Novavax Licenses Matrix-M Adjuvant to Pfizer for $30M Upfront, $500M Milestones
Novavax granted Pfizer a non-exclusive license to use its Matrix-M adjuvant in vaccine formulations, receiving a $30 million upfront payment. The agreement allows up to $500 million in clinical, regulatory and commercial milestones plus mid-single-digit royalties on future product sales.
1. Novavax Shares Underperform Broad Market
In the most recent trading session, Novavax shares fell by approximately 2%, contrasting with a modest gain across major market indices. Trading volume reached about 12 million shares, representing a 30% increase over the stock’s 30-day average. Analysts attribute the pullback to rotational flows into cyclical and energy sectors, while positioning ahead of upcoming regulatory milestones for the company’s vaccine candidates remains cautious.
2. Strategic Licensing Deal With Pfizer
Novavax has granted Pfizer a non-exclusive license to its Matrix-M adjuvant technology, receiving $30 million in upfront payments. The agreement includes up to $500 million in development and regulatory milestones, plus mid-single-digit royalties on future sales. This partnership diversifies Novavax’s revenue base beyond its own vaccine programs and leverages Pfizer’s global commercial infrastructure, potentially unlocking significant downstream cash flows if milestone triggers are met.